uldn inverse titration protocol final
TRANSCRIPT
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
1/50
Michael Robinson Nov 2013Page 1
UsingUltra Low Dose Naltrexoneto
reduce op iate use and trans i t ion to LDN.
A novel approach for patients withChronic Immune NeurologicalDiseases*to move away from
opiate use to manage symptomsof pain and fatigue.
* Chronic Immune Neurological Diseases of
"C.I.N.D. is a term that covers a wide range
of diseases affecting both the immune and
neurological systems. These include Lyme
disease, ME, CFS, CRPS, Fibromyalgia
(FMS) and MS.
Ultra-Low-Dose Opioid
Antagonists Enhance
Opioid Analgesia and
Reduce Tolerance
Lindsay H. Burns,Todd W.
Vanderah,Hoau-Yan Wang
12/2008; DOI:10.1007/978-1-59745-
197-0_1
ABSTRACT
Ultra-low-dose opioid
antagonists have been
shown to enhance opioid
analgesia and attenuate the
tolerance to analgesic
effects normally seen with
chronic opioid
administration.
Source
http://www.researchgate.net/publication/226837972
_Ultra-Low-
Dose_Opioid_Antagonists_Enhance_Opioid_Analg
esia_and_Reduce_Tolerance
http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/ -
8/13/2019 ULDN Inverse Titration Protocol FINAL
2/50
Michael Robinson Nov 2013Page 2
AcknowledgementsThere are many people I need to acknowledge and thank for assisting with thecompilation of this information. I cannot thank them all but they all have one thing incommon. They advocate for their own health and they; advocate for the health andwell being of others; demanding better treatments against misinformation andapathy.
I also acknowledge the late Thomas Michael Hennessy, Jr. who passed away onSeptember 9, 2013 in Florida USA after 25 years of living with the debilitating symptomsof a Chronic Immune Neurological Disease. Thomas knew more than most about thepolitics and problems getting an accurate diagnostic definition as well as focusing themedical community on the multiple causes and effective treatments.see
Remembering Thomas Hennessy Jr. on Pg 50
DisclaimerThis information herein is not medical advice, it does not and should not replacemedical advice. It has been compiled and been made available in the hope thatpatients and medical professionals will become aware of the research and opinionsthat exists on the use and benefits of ULDN and LDN, the increasing use of ULDNand LDN.
Creative Commons Use / CCL Statement
Share and share alike ....
http://en.wikipedia.org/wiki/Share-alike
http://en.wikipedia.org/wiki/Share-alikehttp://en.wikipedia.org/wiki/Share-alikehttp://en.wikipedia.org/wiki/Share-alike -
8/13/2019 ULDN Inverse Titration Protocol FINAL
3/50
Michael Robinson Nov 2013Page 3
ContentsAcknowledgements ................................................................................................... 2
Disclaimer ................................................................................................................. 2
Creative Commons Use / CCL Statement ................................................................. 2
Open Letter ........................................................................................................... 5
Aims and benefits of the ULDN Approach: ................................................................ 6
Protocol Overview ..................................................................................................... 8
A novel role for agonists ...................................................................................... 12
Additional Reading .................................................................................................. 17
Treating the cause not just masking symptoms................................................ 18
ULDN .................................................................................................................. 20
Observations by Dr Boris Gimbarzevsky .......................................................... 20
A selection of studies and published works ...................................................... 21
Studied, Recommended, Prescribed & Advocated by... ................................... 29
LDN - Extract from article by Dr Mercola .......................................................... 34
Doses and dilutions for ULDN and LDN ........................................................... 37
A DIY guide to diluting a 50mg tablet for ULDN and LDN liquid. ...................... 38
An important note Re Fillers............................................................................. 40
An important note if you change methods or dispensing pharmacy.................. 40
Pharmacist Dr Skip Lenz comments ................................................................ 41
Improving your capacity for activity - What really does help? .................................. 42
Remembering Thomas Hennessy Jr. ...................................................................... 50
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
4/50
Michael Robinson Nov 2013Page 4
Clinical Success
ULDN reduces Opioid
Tolerance."
"....primary goals I had in using
Naltrexone in my patients was to
see if I could slow the rate of
development of opiate tolerance
in patients on chronic opiatetherapy...."
".... patients have been using
range from 10 micrograms to
100-200 micrograms 2-4 times
daily.
Dr Boris Gimarzevsky
Source and further information:
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html -
8/13/2019 ULDN Inverse Titration Protocol FINAL
5/50
Michael Robinson Nov 2013Page 5
Open Letter
Friday 29th November 2013
To whom it may concern:
The following information introduces a safe and effective approach to supporting thereduction of opiate use for those patients with ME, CFS, FMS who due to post
exertion malaise have difficulty boosting the production of dopamine through
vigorous exercise.
With medical guidance and support the use of ULDN has been shown to:
- reduce opioid tolerance
- assist with the reduction of opioid medications use
With persistence and support to find the individually suitable doses the patient overtime seeks to move from using opioid medication to LDN.
The following information is a compilation of research, online articles and
discussions from doctors, researchers and patients. It is not intended to replace
medical advice but instead to raise awareness of the use of ultra low dose
naltrexone and low dose naltrexone as a safe, cheap and effective option.
References and sources are included as hyperlinks through the document not as
they would usually be references or tabled in an academic paper. This is document
is not intended to be an academic paper or replace professional medical advice butas a compilation of some of the information readily available.
Yours Sincerely
Michael D. Robinson
Sydney, NSW, Australia.
NOTE
ULDN and ULDTX have been used interchangeably in some online discussions.
ULDN = ULTRA Low Dose Naltrexone (ie micrograms usually between 10mcg and 200mcg)
LDN = Low Dose Naltrexone (ie mg usually between 0.5mg and 5mg)
For the purpose of simplicity and clarity for all readers 'mcg' has been used in this document for
'micrograms' instead of the usual ' g'.
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
6/50
Michael Robinson Nov 2013Page 6
Aims and benefits of the ULDN Approach:
The aim of this approach is to:
- reduce opiate tolerance;
- repair of the dopamine system affected by long term opiate medication;
- reduce opiate use
- taper opiate use to zero
- begin using LDN long term
ULDN assists both reducing opioid tolerance and also in chronic pain and auto
immune conditions like ME, Chronic Fatigue Syndrome and Fibromyalgia.
Studies and use of doses as small as nano and pico doses of Naltrexone have been
shown to also benefit. Studies and clinical experience of doctors and patients using
ULDN & LDN for this application show that there is a parabolic response to ultra low
doses. It is therefore more desirable for patients to be able to titrate the dose to find
the optimal dose.
Introducing ULDN assists the patient's recovery from the effects of long term opioid
use. As that recovery improves it may be possible to reduce opioid use with a goal
of tapering opioid use down, to zero use if possible.
Tailoring the treatment and inverse titration of opiate and ULDN medications allows
the patient to take the dose of each medication that maximises their progress
towards LDN use.
This "swap over" needs to be undertaken in a methodical, slow and steady manner
to first support the recovery of the dopamine receptors and production to support the
aim of moving towards replacing opiate use with LDN.
NOTE : This approach is in tended as part of an overal l comp rehensive
appro ach to regain ing health and wel l being.
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
7/50
Michael Robinson Nov 2013Page 7
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
Clinical Success
More effective long term
treatment with LDN.
" (for)...... individuals suffering
from neuropathic pain, thisregime worked quite impressive
in our hands."
August 2010, Jan M. Keppel
Hesselink, MD, PhD
Source and further information:
http://www.neuropathie.nu/treatme
nt/low-dose-naltrexone-for-
neuropathic-pain.html
http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf -
8/13/2019 ULDN Inverse Titration Protocol FINAL
8/50
Michael Robinson Nov 2013Page 8
--- Opiate titration
----ULDN (ug / mcg) to LDN (mg) titration
Protocol Overview
Inverse titration of ULTRA LOW DOSE NALTREXONE and opioid medicationundertaken with physicians and patients working together is for the long term benefit of
the patient's well being. While some patients may find benefit in the first few weeks, itmay take other patients a few months to find a dose where the benefits of ULDN beginto be noticed.
The short acting immediate release ULDN is taken once daily around 10pm. This iswhen the body normally starts producing more dopamine and dopamine receptors.As ULDN only stays in the body for about 4 hours the "rebound" from even thesmallest short acting doses of ULDN causes the body produce more dopamine anddopamine receptors.
NOTE : The graphic below is an approximation for illustrative purposes only. It is not toscale and individual decisions should be made with medical advice consideringindividual situations.
1. Approx 3
months after
starting ULDN
begin slow
reduction of
opiates
2.After ULDNstarts to
support
dopamine then
reduce opioid
use, gradually
increasing
ULDN as able.
3. shows
gradual
increases of
ULDN doses
4. 14 days
after Opioid
zero use
taper ULDN
to LDN
5. gradual &
patient
increases to
LDN as
appropriate.
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
9/50
Michael Robinson Nov 2013Page 9
ULDN used in this way supports the repair of problems caused by long term opioidmedication use.
This problem is commonly referred to as " post opioid withdrawal syndrome".
Doctors commonly recommend patients re invigorate the dopamine system throughvigorous exercise but due to the complications such as "post exertion malaise", POTS orPostural Orthostatic Tachycardia Syndrome and Orthostatic Dysautonomia in patientswith ME/CFS/FMS, this type of exercise is not possible and causes serious worseningof their condition.
ULDN allows for a more controlled way to support recovery and reduce opioid usewithout the unnecessary complications of rapidly withdrawing opioid medications untilthe patient requires less medication. As the ULDN supports the "repair" of the patient'sdopamine receptors and production the opioid medication can be gradually reduced.
It should be kept in mind that patients that have persisting pain may struggle to achievethe goal of zero opioid use. LDN has been shown to reduce pain in patients howeverthe transition may be more challenging than both physician and patient hopes andrequire patience. . With patience and an experienced multi-disciplinary the aim is tocompletely swap the patient over from the ULDN + opiate mix and onto LDN as a longterm beneficial medication.
Although ULDN assists to repair the dopamine system it is a slow process and requirespatience the long term goal is to begin LDN without opiate use.
See also
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf -
8/13/2019 ULDN Inverse Titration Protocol FINAL
10/50
Michael Robinson Nov 2013Page 10
ULDN dose requires individual titration
"The dose/ respon se cu rve of n al trexone po tent iat ion of analgesia appears to be
parabol ic; no response at too low a dose, a maximum response at a higher dose and then
decreasing effectiveness as one continues to increase naltrexone dose. At some point, the
dose of naltrexone will be high enough and it will be algesic; ie increase pain as it assumes
its expected opiate receptor blocking role. The dose of naltrexone that will antagonize
exogenous opiates and increase pain is quite variable among individuals. The lowest dose
I've seen put a chronic opiate user into withdrawal has been 1 mg; naltrexone is a
competative opiate antagonist and so to treat this withdrawal one needs to merely take more
opiates." Source:
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
see alsoObservations by Dr Boris Gimbarzevsky p20
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html -
8/13/2019 ULDN Inverse Titration Protocol FINAL
11/50
Michael Robinson Nov 2013Page 11
Increases to ULDN dose should be made slowly and as a general guide variousdiscussions seem to indicate that after 3 or more months it will be much easier to
reduce opioid use reduced by 10% every 1 to 3 months.
This is a general guide for illustrative purposes only and individual approachesshould be guided by the ability of the patient to sustain a reduction in opioid use inconsultation with their treating doctors.
The longer the patient has been on opioid medications the more difficult it will be toreduce the dose. As a general guide it should be noted that the smaller the dosesbecome it may become harder to reduce opiate use however with ULDN thesedifficulties are lessened.
It should be kept in mind that the dopamine system being repaired has been alteredby the introduction of prescribed opioid medications taken long term and so and willtake time to repair. While all other multidisciplinary approaches to support thisprotocol should be encouraged it does need to be kept in mind that it will be aprocess that will happen at the patient's individual pace.
Patience and persistence will increase success as this may take many, and in factshould, be undertaken over months or even years rather than days or weeks.
After 10 - 14 days of no opioid use the dose of ULDN can be gradually increased to0.5mg (LDN levels for immune support) per day as either a single daily dose or splitdose and increased thereafter according to LDN protocols .
Ultra-low-dose opioid antagonists have been shown to enhance opioid
analgesia and attenuate the tolerance to analgesic effects normally
seen with chronic opioid administration. (Lindsay H. Burns,Todd W.Vanderah,Hoau-Yan Wang)
See: http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerance .
http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/researcher/14687245_Hoau-Yan_Wang/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/15292617_Todd_W_Vanderah/http://www.researchgate.net/researcher/23505070_Lindsay_H_Burns/ -
8/13/2019 ULDN Inverse Titration Protocol FINAL
12/50
Michael Robinson Nov 2013Page 12
A novel role for agonists
Naloxone
Naltrexone and Naloxone (see p. 13) are commonly confused though have similar
pharmaceutical uses in some oral medications included for their anti injecting abuse
blockade role. Naloxone's two main uses are in anti injection abuse inclusion in
combination opioid medications with Naloxone combined and as a emergency
overdose reversal treatment.
See MIMS orhttp://en.wikipedia.org/wiki/Naloxonefor more information.
Some studies of the use of ultra low dose naloxone alone have been undertaken,
(mostly IV infusions) more common use of Naloxone is in combination medications
mentioned above such as Targin, Suboxone or Buprenorphine.
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
Targin (combination of Oxycontin and Naloxone) is often used by doctors for its
decreased opioid effect on the bowel but ULDN has a greater beneficial effect than
Naltrexone has. Other combined medications include Suboxone but these
combinations do not allow for individual titration of either Naloxone (similar to
naltrexone) or of the opiate dose.
In recent years the price of Naloxone has increased significatly internationally in
stark contrast to the low cost of Naltrexone.
Suboxone and Buprenorphine are both relatively new medications compared to
Naltrexone neither reduce tolerance and weaning of either medication is known to be
extremely difficult.
Current approx costs (in Australia) depending on dose for Targin, Suboxone or
Buprenorphine is around $ 1 .56 / day e.g. Buprenorphine
(oxycodone hydrochloride 20 mg + naloxone hydrochloride 10 mg tablet: modified release)
http://www.pbs.gov.au/medicine/item/8935G
though some options are significantly more expensive even on the PBS schedule.
Note the dose of Naloxone included in these medications is generally considered to
be for anti injection abuse purposes combination medications and has not been
extensively studied or used for the purposes of this protocol to support the dopamine
system, immune system and move the patient off opiates and onto LDN.
http://en.wikipedia.org/wiki/Naloxonehttp://en.wikipedia.org/wiki/Naloxonehttp://en.wikipedia.org/wiki/Naloxonehttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.pbs.gov.au/medicine/item/8935Ghttp://www.pbs.gov.au/medicine/item/8935Ghttp://www.pbs.gov.au/medicine/item/8935Ghttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://en.wikipedia.org/wiki/Naloxone -
8/13/2019 ULDN Inverse Titration Protocol FINAL
13/50
Michael Robinson Nov 2013Page 13
Naltrexone 50mg extended release
Used at 50mg and 300mg doses Naltrexone is commonly as an opioid blockade medication
for heroin and alcohol addicts. At these doses is acts as an agonist to block opiates and
also reducing cravings for intoxicating substances.
Low Dose Naltrexone immediate releaseAt 0.025 to 5mg LDN has a beneficial effect on the immune and dopamine system.Immediate release LDN has a half life of 4 hours. LDN's role in this protocol is the repair ofthe opioid growth factor, dopamine and immune systems. At doses under 1mg has beenshown to not have a blockade effect that could precipitate withdrawals in patients usingopioid medications.
After patients have stopped using opiates for 14 days they can start on LDN. Generallystarting at 0.5mg and working up to 1.5mg and then even slower to around 4.5mg/ dayeither as a single or split dose. Where patients may need to take both LDN and painmedications more information is available on the LDN information sites regarding the use ofTramadol with LDN.
Dr Chris Steele, MBE, speaks about using LDN as a first choice as it effective, does no harmand is a safe drug. http://www.youtube.com/watch?v=CVpjsDK0LPA
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
Additional Reading
A e-book of resources and cases of LDN use for the First International LDN Awareness
Week 2009 by Julia Schopick see: http://preventionx.com/The-Faces-of-Low-Dose-
Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.html
Low dose naltrexone for neuropathic painhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.html
The Fibromyalgia drugs your doctor (probably) knows nothing about.
This article by Cort Johnsonhttp://www.cortjohnson.org/ one of the leading advocates forCFS and Fibromyalgia research, awareness and improved treatments explains this opioidantagonist .. .. "Opio id AntagonistsMore extensive use of opioid antagonists as well as the introduction of novel microglial activation
inhibitors (miRNA) pose exciting new possibilities for the treatment of FMS.Ablin and Buskila
It may seem strange to target drugs that knock down one of the main pain inhibitingsystems in the body but the opioid receptors in many FM patients appear to filled andelevated opioid activity in the brain can cause increased, not decreased pain sensitivity.
Low Dose Naltrexone (LDN)An opioid antagonist long used by people with fibromyalgiafor relief, LDN finally got a clinical trial and it was successful. At the low doses used in thetrial, Ablin and Busklin suggested LDNs effectiveness in FM may have been more due toanti-inflammatory effects than to opioid antagonism....."
seehttp://www.prohealth.com/library/showarticle.cfm?libid=18225
see also http://ldninfo.org/others.htm
http://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdf
http://www.youtube.com/watch?v=CVpjsDK0LPAhttp://www.youtube.com/watch?v=CVpjsDK0LPAhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.cortjohnson.org/http://www.cortjohnson.org/http://www.cortjohnson.org/http://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.prohealth.com/library/showarticle.cfm?libid=18225http://ldninfo.org/others.htmhttp://ldninfo.org/others.htmhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://www.bwmbagus.demon.co.uk/BobsDocs/0-LDN-Side-effects.pdfhttp://ldninfo.org/others.htmhttp://www.prohealth.com/library/showarticle.cfm?libid=18225http://www.cortjohnson.org/http://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://preventionx.com/The-Faces-of-Low-Dose-Naltrexone---HONEST-MEDICINE-My-Dream-for-download-w5661.htmlhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.youtube.com/watch?v=CVpjsDK0LPA -
8/13/2019 ULDN Inverse Titration Protocol FINAL
14/50
Michael Robinson Nov 2013Page 14
Ultra Low Dose Naltrexone immediate release
ULDN (1microgram - 500micrograms)
Even at pico, nano and ultra low doses naltrexone has beneficial effects on the
immune and dopamine systems. The dose requires titration for individual patients as
at these low doses the beneficial dose can be parabolic and requires individualtitration to find the dose that best suits. As patients improve the dose can be
increased accordingly.
It is important that in prescribing and dispensing ULDN fillers used in tablets and
capsules not interfere with the immediate release. An experienced LDN
compounding pharmacy be used or a suitable 50mg tablet be dissolved in distilled
water by the patient and the appropriate liquid dose be measured.
ULDN has been studied and shown to:
- prevent injection abuse (like Naloxone) in oral medications without affecting theopioid effect.- reduce opioid tolerance,- improves immune support function.- is not sufficiently large enough dose to cause blockade (ie does not causewithdrawals)
Current approximate costs of LDN and ULDN in Australia
For Australian purposes and using one 50mg Naltrexone tablet per month diluted in
distilled water to measure out liquid dose of LDN or ULDN the cost is approx 9c /day.
ie $136 for 30 x 50mg tablets
= $2.72 per month
= 9 cents per day
Source:
http://www.pbs.gov.au/medicine/item/8370M
" (for)...... individuals suffering from neuropathic pain, this regimeworked quite impressive in our hands."
August 2010, Jan M. Keppel Hesselink, MD, PhD
http://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.html
http://www.pbs.gov.au/medicine/item/8370Mhttp://www.pbs.gov.au/medicine/item/8370Mhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.neuropathie.nu/treatment/low-dose-naltrexone-for-neuropathic-pain.htmlhttp://www.pbs.gov.au/medicine/item/8370M -
8/13/2019 ULDN Inverse Titration Protocol FINAL
15/50
Michael Robinson Nov 2013Page 15
Opioid Antagonists in Pain Management
Available evidence suggests that the
opioid antagonists naloxone and
naltrexone offer potential benefits for
enhancing opioid analgesia as well as
monotherapy for managing certain
challenging pain conditions.
By Stewart B. Leavitt, MA, PhD
ULDN science published studies
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html -
8/13/2019 ULDN Inverse Titration Protocol FINAL
16/50
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
17/50
Michael Robinson Nov 2013Page 17
ULDN and LDN Naltrexone offers many benefits over Naloxone - as
Naltrexone benefits neuropathic pain conditions, "rests" the opioid
receptor system, enhancing analgesia while overcoming prior
opioid tolerance or hyperanalgesia.
SeeError! Reference source not found.http://preventionx.com/download.php?id=5675
Additional Reading
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
Standford Researchers get to the root of stopping the pain rather thanmasking it .
http://alumni.stanford.edu/get/page/magazine/article/?article_id=66226
....."In a 2013 study by Younger's team, 31fibromyalgiapatients treated with low
doses of a drug called Naltrexonethat inhibits microglial cells in the CNS reported
significantly less daily painon average compared with a placebo pill.
The link between the immune system and chronic pain is an unfolding story that
encompasses other types of chronic pain, including complex regional pain
syndrome.David Clark, a professor of anesthesia who studies the condition, notesthat some of its features" .... "the development of neurological problemsare
reminiscent of autoimmune disorders." *
* (i.e. ULDN and LDN helps the improvement of such autoimmune disorders)
For more information on this study see
http://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.html
http://preventionx.com/download.php?id=5675http://preventionx.com/download.php?id=5675http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://updates.pain-topics.org/2012/03/low-dose-naltrexone-eases-fibromyalgia.htmlhttp://alumni.stanford.edu/get/page/magazine/article/?article_id=66226http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://preventionx.com/download.php?id=5675 -
8/13/2019 ULDN Inverse Titration Protocol FINAL
18/50
Michael Robinson Nov 2013Page 18
The Journal of PainVolume 9, Issue 8, Pages 700-713,August 2008
Oxycodone Plus Ultra-Low-Dose
Naltrexone Attenuates Neuropathic
Pain and Associated -Opioid
ReceptorGsCoupling
Tally M. Largent-Milnes,Wenhong Guo, Hoau-Yan Wang,Lindsay H. BurnsToddW. Vanderah
Treating the cause not just masking symptoms
A presentation about the history and need for improvements to treating chronic pain.http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf
There are many other links and attachments referred to throughout the rest of thisdocument that address ULDN more specifically however it is prudent to put thisdiscussion in context. Throughout this document are references to the need to improvetreatment of Chronic Pain. This presentation explains the importance of a newapproach.
Traditionally anyone with chronic pain has been prescribed pain masking medication,the long term use of which does not improve their chronic pain nor their health.
For those with chronic immune neurological diseases including Lyme, ME, CFS andFibromyalgia as too often when their treating doctors have not had a test result to point
to as a cause of the pain start to blame the patient and suggest the pain is imaginary.
Thankfully as more studies give more doctors information they can understand aboutwhat the disease is doing to their patient they can better provide treatments morespecific to the causes rather than simply guessing at treatments and prescribingsymptom masking pain medications.
Pages 1 - 15 of the document outlines historical use of opioids. This information iscovered in many places but for the purposes of this document it is at least worthmentioning in passing.http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf
The historical context explains the history of theold approach for chronic pain conditions includingFibromyalgia. (Note there is extensive publishedmaterial about the difficulties of treatingFibromyalgia, tolerance and poor response toopioids as well as the need to consider Lyme,mold and other causes in order to address thecause rather than simply make the condition worseby exacerbating a chronic pain condition with longterm opioid use problems. These include effects
on hormones, the dopamine system as well ashyper analgesia.)
In this regard the chart on page 15of
http://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdf
also discusses Magnesium use to reduce pain. Addressing the issue of supplements(including magnesium and Vitamin D3 as well as tailoring dietary approaches toeliminate food intolerances and addressing issues as far ranging as muscle and jointinjuries to viral, mold and chemical exposure are also necessary).
http://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2http://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfhttp://www.janussc.org/downloads/Opioids_and_Post_Op_Pain_Management.pdfmailto:[email protected]://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/issues?issue_key=S1526-5900(08)X0008-2 -
8/13/2019 ULDN Inverse Titration Protocol FINAL
19/50
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
20/50
Michael Robinson Nov 2013Page 20
ULDN
Observations by Dr Boris Gimbarzevsky
Selected extracts
".... Even though the doses of naltrexone may seem miniscule, there are some veryinteresting things that seem to happen with endogenous opiate systems when oneuses naltrexone in conjunction with opiates.
Dr. Boris Gimbarzevsky 20/4/2004
Source:http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
"...One of the primary goals .... slow the rate of development of opiate tolerance inpatients on chronic opiate therapy."
Dr. Boris Gimbarzevsky 20/4/2004
Source:http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
"....If the result was due to placebo effect, then one would expect pain relief at the 1microgram dose. This dose did absolutely nothing for her and once she hit 10micrograms good analgesia resulted. Now the placebo effect is thought to bemediated by endorphins as placebo analgesia can be blocked with intravenous
naloxone and it could be that my action of giving her the naltrexone resulted inincreased endorphin release and the ULDNTX potentiated these endorphin effects.She continued to use the naltrexone with good ..."
Dr. Boris Gimbarzevsky 20/4/2004
Source:http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
Generally I suggest to patients that they experiment with combining microgramdoses of naltrexone with opiate analgesics and I have seen reductions ...... in opiate
analgesic doses when this approach has been used. One indication that a drug isdoing something is when patients ask for more of it. I've had patients use opiatesand naltrexone in combination and then come back asking for more naltrexone as itseemed to be helping with analgesia.
Dr. Boris Gimbarzevsky 20/4/2004
Source:http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html
More at http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlandhttp://drgimbarzevsky.com/Naltrexone/
http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/http://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.htmlhttp://drgimbarzevsky.com/Naltrexone/Low_Dose_Naltrexone_Observations1.html -
8/13/2019 ULDN Inverse Titration Protocol FINAL
21/50
Michael Robinson Nov 2013Page 21
A selection of studies and published works
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
The following few pages are just a selection of the published studies listed on
Sciece.gov into the use of Ultra Low Dose Naltrexone
For more see http://ldninfo.org/ldn_trials.htm
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
Ultra-low-dosenaltrexonereduces the rewarding potency ofoxycodone and relapse vulnerability in ratsMicrosoft Academic SearchUltra-low-doseopioid antagonists have been shown to enhance opioid analgesia and
alleviate opioid tolerance and dependence. ............ potential of oxycodone+ultra-low-dosenaltrexone(NTX) versus oxycodone alone. ..........Francesco Leri; Lindsay H. Burns2005-01-01
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
Human abuse liability assessment of oxycodone combined with ultra-low-dosenaltrexoneMicrosoft Academic Search
......" Preclinical and clinical studies have shown that opioids combined withultra-low-dosenaltrexone(NTX) may have increased\\u000a analgesic potency and have
suggested reduced abuse or dependence liability. ....."David Andrew Tompkins; Ryan K. Lanier; Joseph A. Harrison; Eric C. Strain; George E.Bigelow
2010-01-01
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
Ultra-low-dosenaltrexonesuppresses rewarding effects of opiatesand aversive effects of opiate withdrawal in rats
Microsoft Academic SearchRationale Ultra-low-doseopioid antagonists enhance opiate analgesia and attenuatetolerance and withdrawal........ Objectives To determine whether ultra-low-
dosenaltrexone(NTX) coadministration alters the rewarding effects of opiates or the
aversive\\u000a effects of opiate withdrawal.\\u000a \\u000a \\u000a \\u000a
Methods We used the conditioned place preference (CPP) and conditioned place
aversion (CPA) paradigms to assess whether ultra-low-dose\\u000a NTX alters the
acute rewarding effects of oxycodone or morphine, or theMary C. Olmstead; Lindsay H. Burns2005-01-01
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://ldninfo.org/ldn_trials.htmhttp://ldninfo.org/ldn_trials.htmhttp://ldninfo.org/ldn_trials.htmhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/m22348m5v6up5779.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.springerlink.com/index/uq763g1v869466p6.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.paintherapeutics.com/publications/Leri_2005.pdfhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://ldninfo.org/ldn_trials.htmhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf -
8/13/2019 ULDN Inverse Titration Protocol FINAL
22/50
Michael Robinson Nov 2013Page 22
Oxycodone Plus Ultra-Low-DoseNaltrexoneAttenuates NeuropathicPain and Associated ?-Opioid ReceptorG s CouplingMicrosoft Academic SearchBoth peripheral nerve injury and chronic opioid treatment can result in hyperalgesia
associated with enhanced excitatory neurotransmission at the level of the spinal cord.
Chronic opioid administration leads to a shift in ?-opioid receptor (MOR)G protein
coupling from Gi\\/o to Gs that can be prevented by cotreatment with an ultra-low-
doseopioid antagonist. In this study, using lumbar spinal cord tissueTally M. Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H. Burns; Todd W.Vanderah2008-01-01
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
http://www.jpain.org/article/S1526-5900(08)00480-X/abstract
Enhancing acupuncture by low dosenaltrexone.PubMedTo find appropriate and effective treatment options for chronic pain syndromes is a
challenging task. Multimodal treatment approach has been gaining acceptance for
chronic pain. However, combining treatments, such as acupuncture, with rationalpharmacology is still in its infancy. Acupuncture influences the opioid and cannabinoid
system through releasing endogenous receptor ligands. Low dosenaltrexonealso acts
on both these systems, and upregulates the opioid and cannabinoid receptors. The
authors hypothesise that low dosenaltrexonecould enhance the pain-relieving effect of
acupuncture. PMID:21415049Hesselink, Jan M Keppel; Kopsky, David J2011-03-17
http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.html
http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://academic.research.microsoft.com/http://academic.research.microsoft.com/http://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmedhttp://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://www.ncbi.nlm.nih.gov/pubmed/21415049http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.science.gov/topicpages/u/ultra-low+dose+naltrexone.htmlhttp://academic.research.microsoft.com/http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298http://science.gov/scigov/link.html?type=RESULT&redirectUrl=http://academic.research.microsoft.com/Publication/30329298 -
8/13/2019 ULDN Inverse Titration Protocol FINAL
23/50
-
8/13/2019 ULDN Inverse Titration Protocol FINAL
24/50
Michael Robinson Nov 2013Page 24
Recent Patents on CNS Drug Discovery, 2010, 5, 210-220
PTI-609: A Novel Analgesic that Binds Filamin A to Control OpioidSignalingLindsay H. Burns,and Hoau-Yan Wang
Pain Therapeutics Inc., San Mateo, CA,Dept. of Pharmacology and Physiology, CUNY Medical School, New York,NY, USAReceived: June 4, 2010; Accepted: August 9, 2010; Revised: August 13, 2010
http://www.paintrials.com/publications/pti609_JournalArticle.pdf
Opiate Receptors and Antagonists: From Bench to Clinic
edited by Reginald L. Dean, Edward J. Bilsky, S. Stevens Negus
source
http://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&sour
ce=bl&ots=z2opO-
l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepag
e&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=false
see p 9 for more information about the benefits of the combination of opioids with
ULDN
For more scholarly discussion of the workings of Naltrexone seeAntidotes: Advances in Research and Application: 2011 Edition: Scholarly
Brief
Ch 2 pp 28...
http://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=false
..." Combined with opiates, ultra-low-dose naloxone or naltrexone can
enhance and prolong the analgesia of the opiate alone and prevent or
attenuate opioid ..."
http://www.paintrials.com/publications/pti609_JournalArticle.pdfhttp://www.paintrials.com/publications/pti609_JournalArticle.pdfhttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=JG64gRbV3DYC&pg=PA28&lpg=PA28&dq=:+A+Novel+Analgesic+that+Binds+Filamin+A+to+Control+Opioid+Signaling&source=bl&ots=5Vj2XBc6s3&sig=DNyQxUHFauxDTtD6F1lApullUGM&hl=en&sa=X&ei=0qCfUueNNeayiQfe2ID4DA&ved=0CEoQ6AEwAw#v=onepage&q=%3A%20A%20Novel%20Analgesic%20that%20Binds%20Filamin%20A%20to%20Control%20Opioid%20Signaling&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://books.google.com.au/books?id=zqj2vy6VFUcC&pg=PA9&lpg=PA9&dq=Opioid%22ultra+low+dose+naltrexone%22&source=bl&ots=z2opO-l_e2&sig=7WkwQykEY5uH15J6cSrftqDcxZY&hl=en&sa=X&ei=Wm2PUvzZIq3xiAfsoYDACw&ved=0CHIQ6AEwCA#v=onepage&q=Opioid%22ultra%20low%20dose%20naltrexone%22&f=falsehttp://www.paintrials.com/publications/pti609_JournalArticle.pdf -
8/13/2019 ULDN Inverse Titration Protocol FINAL
25/50
Michael Robinson Nov 2013Page 25
Why so much excitement about LDN if my doctor doesn't know about it?
LDN
"Easily compoundable at local pharmacies LDN will never get financial support from
drug companies for drug trials but studies are being done. (The FM trials, below,
were sponsored by the American Fibromyalgia Association.) In 2013, 23 LDN trials
(underway or completed) on disorders ranging from fibromyalgia to alcoholism abuse
to multiple sclerosis to narcotics withdrawal ...."http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-
standard-treatment-chronic-fatigue-syndrome-fibromyalgia/
Read more: Low Dose Naltrexone Becoming Standard Treatment for Chronic
Fatigue Syndrome and Fibromyalgia http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-
fibromyalgia/
De Meirleir begins this latest video talk by referring to the exciting but small
LDN/Fibromyalgia study at Stanford. (Stanfords 2009study found that LDN
significantly reduced pain, fatigue, and stress, and helped to improve sleep and
reduce gut issues and headaches.
De Meirleir explained that LDN is an opiate receptor blocker and is used in very
small doses (0.5-5.5 mg/day) relative to its normal dosing (5 grams, which is 5000
mg). It turns out that the partial blockage of the opioid receptors tricks the brain into
producing more of its own opiates, thus reducing pain and improving sleep (but not
generally reducing fatigue).
Read more: Low Dose Naltrexone Becoming Standard Treatment for Chronic
Fatigue Syndrome and Fibromyalgia more athttp://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-
standard-treatment-chronic-fatigue-syndrome-fibromyalgia/
I want to make a plug for Low Dose Naltrexone Dr. Nancy KlimasSimmaronRoundtable Meeting: Read more: Low Dose Naltrexone Becoming StandardTreatment for Chronic Fatigue Syndrome and Fibromyalgiahttp://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/
See more atThe Doctor's Medical Library : Low Dose Naltrexone by Ron Kennedy M.D.http://www.medical-library.net/content/view/533/41/
http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/
See clinical review of evidence http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdf
http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.medical-library.net/content/view/533/41/http://www.medical-library.net/content/view/533/41/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://pain-topics.org/pdf/OpioidAntagonistsForPain.pdfhttp://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.cortjohnson.org/treating-chronic-fatigue-syndrome-mecfs/drugs-for-chronic-fatigue-syndrome-mecfs-treatment/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/http://www.medical-library.net/content/view/533/41/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/http://www.cortjohnson.org/blog/2013/08/28/mecfs-doc-asserts-low-dose-naltrexone-becoming-standard-treatment-chronic-fatigue-syndrome-fibromyalgia/ -
8/13/2019 ULDN Inverse Titration Protocol FINAL
26/50
Michael Robinson Nov 2013Page 26
More books are being published like this one below - see the description for more
information about the history and uses of LDN
The Promise Of Low Dose Naltrexone Therapy: Potential
Benefits in Cancer, Autoimmune, Neurological and Infectious
Disorders [Paperback]
Elaine A. Moore(Author),Dr. Yash P.
Agrawal(Foreword),Samantha Wilkinson(Collaborator)
http://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230
&sr=1-1&keywords=low+dose+naltrexone
Publication Date: December 1, 2008| ISBN-
10:0786437154 | ISBN-13:978-0786437153
Naltrexone is an opiate antagonist drug developed in
the 1970s and approved by the FDA in 1984 for opiate
and drug abuse treatment. When used at much lower
doses in an off-label protocol referred to as low dose
naltrexone (LDN), the drug has been shown to halt
disease progression in Crohn's disease and certain
cancers, to reduce symptoms in multiple sclerosis and
autism, and to improve numerous autoimmune and
neurodegenerative conditions, including Parkinson's
disease and amyotrophic lateral sclerosis (ALS).
Grounded in clinical and scientific research, this book
describes the history of naltrexone, its potential
therapeutic uses, its effects on the immune system, itspharmacological properties, and how the drug is
administered. It also lists fillers and compounding
pharmacies, doctors who prescribe LDN, and patient
resources, and includes interviews with LDN patients
and researchers.
http://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1http://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1http://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/Promise-Low-Dose-Naltrexone-Therapy/dp/0786437154/ref=sr_1_1?s=books&ie=UTF8&qid=1360756230&sr=1-1&keywords=low+dose+naltrexonehttp://www.amazon.com/s/ref=ntt_athr_dp_sr_3?_encoding=UTF8&field-author=Samantha%20Wilkinson&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/s/ref=ntt_athr_dp_sr_2?_encoding=UTF8&field-author=Dr.%20Yash%20P.%20Agrawal&search-alias=books&sort=relevancerankhttp://www.amazon.com/Elaine-A.-Moore/e/B001JRZ6RA/ref=ntt_athr_dp_pel_1 -
8/13/2019 ULDN Inverse Titration Protocol FINAL
27/50
Michael Robinson Nov 2013Page 27
Oxytrex Studies highlight need for inverse titration of
doses.
The study and patent of a combination drug called
"Oxytrex" (Oxycontin plus Ultra-low dose Naltrexone)
as single medication has made some progress intothis area of combining ultra low dose natrexone with
opioid use. It also has application as an abuse
resistant prescription medication.
see p.4. of Pharma Note Jan 2013
http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf
There is enthusiasm for a combination medication suchas Oxytrex based on both the abuse resistant concernsas well as the opioid tolerance prevention. FDAapproval of Oxytrex is still undetermined.
The Oxytrex concept has exciting possibilities in theapplication of managing pain and reducing opioidtolerance if the medication were to be available.
However for those seeking to reduce opioid medicationand move onto LDN taking ULDN and opioid doses asindividual medications and titrating the doses inverselyallows for a dose by dose tailoring of each medication.
see alsohttp://opioids.com/tolerance/oxytrex.htm
and
Journal : Clinical Medicine Insights: Therapeutics
Ultra-Low-Dose Naloxone or Naltrexone to
Improve Opioid Analgesia: The History, the
Mystery and a Novel Approach
http://www.la-press.com/ultra-low-dose-naloxone-or-
naltrexone-to-improve-opioid-analgesia-the--article-
a2351
Clinical MedicineInsights: TherapeuticsR e v i ewClinical Medicine Insights: Therapeutics
2010:2 857Ultra-Low-Dose Naloxone or
Naltrexone to ImproveOpioid Analgesia: The
History, the Mystery and a
Novel Approach
Lindsay H. Burns1 and Hoau-YanWang21Pain Therapeutics Inc., San Mateo, CA,USA. 2Deparment of Pharmacology andPhysiology, CUNY Medical School,
Abstract: Combining opioid
agonists with ultra-low (typically pg-ng/kg) doses of the opioid
antagonists naloxone or naltrexone
can enhance analgesic efficacy and
decrease certain side effects. Such
combinations have also been shown
to decrease tolerance, dependence
and addictive potential in animals.
We now know that ultra-low-dose
naloxone/naltrexone effects occur by
preventing a G protein coupling
switch (Gi/o to Gs) of the mu opioidreceptor (MOR) that occurs briefly
after acute administration or
persistently after chronic
administration of opioids. The
picomolar binding site for naloxone
or naltrexone in these effects is on
the scaffolding protein filamin A
(FLNA), rather than on opioid
receptors. Interestingly, a second,
nanomolar binding site on FLNA
may disrupt the benefits of binding
the picomolar site, perhapsexplaining why ultra-low-dose
naloxone/naltrexone effects vanish at
just slightly higher doses. A novel
analgesic drug candidate aims to
avoid this issue by binding only the
high-affinity FLNA site, while
simultaneously activating MOR.
Binding this single site on FLNA
also provides anti-inflammatory
activity.Keywords: signaling, filamin A,
naloxone, naltrexone, conditioned placepreference, anti-inflammatory
http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://opioids.com/tolerance/oxytrex.htmhttp://opioids.com/tolerance/oxytrex.htmhttp://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://www.la-press.com/ultra-low-dose-naloxone-or-naltrexone-to-improve-opioid-analgesia-the--article-a2351http://opioids.com/tolerance/oxytrex.htmhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf -
8/13/2019 ULDN Inverse Titration Protocol FINAL
28/50
Michael Robinson Nov 2013Page 28
An Extract from "High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid
ReceptorGs Coupling Underlying Opioid Tolerance and Dependence"
...." Ultra-low-dose opioid antagonists have been shown to enhance opioid
analgesia and attenuate tolerance and dependence, with a mechanism long
hypothesized as a blockade of excitatory signaling opioid receptors[1][4].Ultra-
low-dose opioid antagonists can also reverse hyperalgesia caused by acute, low-
dose opioids to produce analgesia[5].Additionally, ultra-low-dose naltrexone has
recently been shown to attenuate opioid reward or addictive properties ...."
..."....... This high-affinity binding site in c-terminal FLNA therefore appears to
underlie the paradoxical enhancement of opioid analgesia and prevention of
analgesic tolerance and dependence by ultra-low-dose opioid antagonists. Inidentifying the binding site though which ultra-low-dose opioid antagonists prevent
MORGs coupling, our data also reveal an important regulation of MORG protein
coupling by filamin A...."
Source:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554
More information about the studies and development of Oxytrex
Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and
Associated -Opioid ReceptorGsCoupling
Tally M. Largent-Milnes, Wenhong Guo, Hoau-Yan Wang, Lindsay H. Burns, Todd W. Vanderah
Received 14 August 2007; received in revised form 4 February 2008; accepted 7March 2008. published online 12 May 2008.seehttp://www.jpain.org/article/S1526-5900(08)00480-X/abstract
see alsohttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerance
Pharma Note newsletter Vol 28 Issue 4 Jan 2013discusses the various combinationmedications, their developments effects, doses and uses.
pp 1-2 Pharmacology of narcotics (opioids)Pp. 2 and 4 Mechanisms of Abuse resistance and deterrence & opioid receptoreffects p 3 list of FDA approved combination opioid and abuse deterrentcombination medications.p. 4 Novel abuse resistent narcotics under review - includes Oxytrex and safetyof oral combination doses of opioid medications with naloxone and naltrexonecombinations.
See http://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdf
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfmailto:[email protected]://copnt13.cop.ufl.edu/doty/pep/pharmanote/January2013.pdfhttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.researchgate.net/publication/226837972_Ultra-Low-Dose_Opioid_Antagonists_Enhance_Opioid_Analgesia_and_Reduce_Tolerancehttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.jpain.org/article/S1526-5900(08)00480-X/abstracthttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain3http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Wang1http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001554#pone.0001554-Crain1 -
8/13/2019 ULDN Inverse Titration Protocol FINAL
29/50
Michael Robinson Nov 2013Page 29
Studied, Recommended, Prescribed & Advocated by...
The following list of some of the Professors, doctors and researchers who have
published studies, peer review articles and online discussions of ULDN and LDN. It
is by no means an exhaustive list but is indicative of the expertise and experience of
those professionals advocating on behalf of the well being of patients that this cheap,
safe and effective medication be seriously considered and tried.
This list includes;
Dr Sean Mackey, MD, PhDRedlich Professor, Stanford Division of Pain MedicinePresident-elect, American Academy of Pain MedicineAssistant professor of anaesthesia at the Stanford University Medical Center
Research Channel update on Fibromyalgia and pain treatments
see
https://www.youtube.com/watch?v=jtc2JARVpPw
Video Uploaded to You Tube on 1 May 2009
Fibromyalgia is a mysterious disorder of unknown cause characterized by widespread
pain, abnormal pain processing, sleep disturbance, fatigue and often psychological
distress. According to the CDC, fibromyalgia affects an estimated 5 million adults. Dr.
Sean Mackey, assistant professor of anesthesia at the Stanford University MedicalCenter, discusses our current understanding of this cryptic disorder: its pathology,
diagnosis and treatment.
@36 - 39 minutes Dr Mackey discusses long term use of opiates.. can cause more pain than less..
healthy people feel good after working out.. fibro patients feel worse
@ 42 minutes discusses LDN
Source:https://www.youtube.com/watch?v=jtc2JARVpPw
Stanford School of Medicine - Systems Neuroscience and Pain LabFibromyalgia Symptoms are reduced by low-dose naltrexone: A pilot study.Pain Medicine (2009)Jarred W. Younger and Sean C. Mackeyhttp://med.stanford.edu/snapl/research/ldn.html
see alsohttp://www.painmattersfilm.com/
https://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPwhttp://med.stanford.edu/snapl/research/ldn.htmlhttp://med.stanford.edu/snapl/research/ldn.htmlhttp://www.painmattersfilm.com/http://www.painmattersfilm.com/http://www.painmattersfilm.com/http://www.painmattersfilm.com/http://med.stanford.edu/snapl/research/ldn.htmlhttps://www.youtube.com/watch?v=jtc2JARVpPwhttps://www.youtube.com/watch?v=jtc2JARVpPw -
8/13/2019 ULDN Inverse Titration Protocol FINAL
30/50
Michael Robinson Nov 2013Page 30
Catherine Cahill, PhD
University of California
Associate Professor
http://www.anesthesiology.uci.edu/index.shtml
http://www.anesthesiology.uci.edu/research_faculty_cahill.shtml
Dr. Tom GilhoolyMBChB MRCGP (Glasgow)One of the keynote speakers and author of many articles for the LDN Research
Trust Dr Tom G talks about LDN at world conference
Dr Tom Gilhooly is a 46-year-old General Practitioner who has worked in the East End of
Glasgow for the past 16 years. He is a nationally-recognised expert on addiction, and
advises both the Scottish Parliament and the UK Government on drug strategy.
Tom is married with three children, and he also has two dogs.
He has a long-term interest in nutrition, and founded The Centre for Nutritional Studies
(CNS) Ltd in 2002, with the aim of carrying out nutritional research. In the past two years
he has become aware of LDN, and is an enthusiastic supporter of this treatment (as well
as natural treatments) for MS. He now runs an MS clinic in Glasgow.
http://www.ldnresearchtrust.org/node/3
http://www.youtube.com/watch?v=fWrG_UQtbsU
eg See page 3 of:
http://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdf
andhttp://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/
http://www.anesthesiology.uci.edu/index.shtmlhttp://www.anesthesiology.uci.edu/index.shtmlhttp://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.ldnresearchtrust.org/node/3http://www.ldnresearchtrust.org/node/3http://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.skipspharmacy.com/wplog/pharmacy-news/ldn-2008-videos-here/http://www.ldnresearchtrustfiles.co.uk/docs/May%20-%20Newsletter.pdfhttp://www.youtube.com/watch?v=fWrG_UQtbsUhttp://www.ldnresearchtrust.org/node/3http://www.anesthesiology.uci.edu/research_faculty_cahill.shtmlhttp://www.anesthesiology.uci.edu/index.shtml -
8/13/2019 ULDN Inverse Titration Protocol FINAL
31/50
Michael Robinson Nov 2013Page 31
Dr. Tim Gerstmar
https://www.facebook.com/AspireNaturalHealth/posts/10151779725083469
Aspire Natural Health 704 like this.
10 August at 15:00
We are experts at treat ing:
G - Can ultra-low dose naltrexone remove some of the side effects of opioidpainkillers? In the comments section of the same post, George Hendersonand Peter D (a vet anesthesiologist) discuss some preliminary research abouthow ultra-low dose naltrexone (a fraction of LDN) can be given alo